secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001493152-24-011443
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus licenses University of Miami's rose bengal PDAT for eye infections; will form spinout
--------------------------------------------------------------------------------

- Exclusive worldwide license for photodynamic antimicrobial therapy (PDAT) using rose bengal sodium to treat bacterial, fungal, and acanthamoeba keratitis.
- Upfront fee of $10k; 10% royalty on net sales; annual maintenance fees of $1k (years 1-4) then $10k; development milestones up to $55k.
- Company to form a majority-owned NewCo within one year; University gets 5% equity and up to 30% of sublicense income depending on clinical phase.
- Technology supported by two international randomized clinical trials (NCT05110001, NCT06271772) for acanthamoeba/fungal and bacterial keratitis.
- Provectus will supply pharmaceutical-grade rose bengal sodium to NewCo exclusively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315224011443/0001493152-24-011443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315224011443/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer